(Q48018233)

English

Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial

scientific article published on 15 July 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

author name string

D Thaçi

1

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

R Galimberti

2

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

M Amaya-Guerra

3

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

T Rosenbach

4

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

D Robertson

5

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

R Pedersen

6

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

S Yang

7

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

M Kuligowski

8

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

R Boggs

9

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

publication date

15 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

Journal of the European Academy of Dermatology and Venereology

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

28

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

7

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

900-906

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

Factors affecting sleep quality in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial).

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

Psychometric properties of the Medical Outcomes Study Sleep measure

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

Psychometric properties of the MOS (Medical Outcomes Study) Sleep Scale in patients with neuropathic pain

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

Validation and response to treatment of a pruritus self-assessment tool in patients with moderate to severe psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

10 years experience of the Dermatology Life Quality Index (DLQI).

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

Current severe psoriasis and the rule of tens.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

Fatigue in cancer patients compared with fatigue in the general United States population.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-alpha antagonist

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12207

21 January 2018

Identifiers

10.1111/JDV.12207

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23848989

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48018233&oldid=2181670652"